Immunohistochemical Detection of Carcinogen-DNA Adducts and DNA Repair in Mouse Skin

4-Hydroxyaminoquinoline 1-oxide (4HAQO) and (±)-trans-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydroben-zo[a]pyrene (BP-DE)-DNA adducts were immunohisto-chcmically demonstrated in the nuclei of mouse skin using antibodies directed against carcinogen (4HAQO or BP) modified DNA. The specificity of the immunostaining was confirmed by several tests, including preincubation of the antibody with carcinogen modified DNA or related molecules, and digestion of the sections with DNase.Subcutaneous injection of 4HAQO dissolved in isotonic solution into an isolated portion of the mouse skin clamped off with ring-shaped forceps resulted in dose-dependent generation of DNA adducts in the nuclei of epithelial cells, fibroblasts, and panniculus carnosus cells. BP-DNA adducts could also be similarly detected dose-dependently in the nuclei of skin cells after local application of BP-DE. Nuclear staining was absent in animals injected with isotonic solution alone, and the intensity of staining correlated well with the level of unscheduled DNA synthesis (UDS) demonstrated autoradiographically after treatment with 4HAQO. Killing of mice at different time points after a single injection of 4HAQO revealed a gradual decrease in the intensity of the staining. Thus the postulated generation and repair of DNA adducts can be followed at the cellular level using the presently described method. J Invest Dermatol 92:275S–279S, 198

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase‑2 (SHP2)

The ubiquitously expressed protein tyrosine phosphatase SHP2 is required for signaling downstream of receptor tyrosine kinases (RTKs) and plays a role in regulating many cellular processes. Genetic knockdown and pharmacological inhibition of SHP2 suppresses RAS/MAPK signaling and inhibit the proliferation of RTK-driven cancer cell lines. Here, we describe the first reported fragment-to-lead campaign against SHP2, where X-ray crystallography and biophysical techniques were used to identify fragments binding to multiple sites on SHP2. Structure-guided optimization, including several computational methods, led to the discovery of two structurally distinct series of SHP2 inhibitors binding to the previously reported allosteric tunnel binding site (Tunnel Site). One of these series was advanced to a low-nanomolar lead that inhibited tumor growth when dosed orally to mice bearing HCC827 xenografts. Furthermore, a third series of SHP2 inhibitors was discovered binding to a previously unreported site, lying at the interface of the C-terminal SH2 and catalytic domains